Ireland’s crucial pharmaceutical sector appears to have largely avoided a new US tariff rate for now, amid a broader 20% tax imposed on other goods from the European Union.
But the industry, which accounts for a large portion of Irish exports, may be subjected to harsh tariffs at a later date as the White House seeks to increase domestic production.
